In the last 12 months, insiders at BIO-TECHNE Corp ($TECH) filed 194 transactions with the SEC: 0 open-market purchases totaling $0 and 10 sales totaling $5,546,075. Net insider sentiment: net selling.
BIO-TECHNE Corp operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- Hippel James (CFO) — 27 transactions totaling $25,050,418
- Kelderman Kim (Chief Executive Officer) — 26 transactions totaling $11,251,878
- BAUMGARTNER ROBERT V (Director) — 10 transactions totaling $2,850,836
- Nusse Roeland (Director) — 6 transactions totaling $2,133,169
- HIGGINS JOHN L (Director) — 16 transactions totaling $1,211,908
View all SEC Filings for BIO-TECHNE Corp (TECH).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Crouse Steven C. | President - Diag & Spatial Bi | A | Stock Option (right to buy) | 1911 | $0.00 | 111,053.0000 | 156,999,000 | 1.75% | 0.00% |
| March 2, 2026 | Crouse Steven C. | President - Diag & Spatial Bi | A | Performance Restricted Stock Units | 2387 | $0.00 | 2,387.0000 | 156,999,000 | 9999.99% | 0.00% |
| March 2, 2026 | Crouse Steven C. | President - Diag & Spatial Bi | A | Restricted Stock Units | 735 | $0.00 | 15,768.0000 | 156,999,000 | 4.89% | 0.00% |
| Feb. 17, 2026 | Herr Amy E. | Director | S | Common Stock | 1976 | $59.11 | 2,880.0000 | 156,999,000 | 40.69% | 0.00% |
| Feb. 3, 2026 | Herr Amy E. | Director | M | Restricted Stock Units | 38 | $0.00 | 1,447.0000 | 156,999,000 | 2.56% | 0.00% |
| Feb. 3, 2026 | Herr Amy E. | Director | M | Common Stock | 38 | $0.00 | 4,872.0000 | 156,999,000 | 0.79% | 0.00% |
| Feb. 3, 2026 | Herr Amy E. | Director | F | Common Stock | 16 | $64.63 | 4,856.0000 | 156,999,000 | 0.33% | 0.00% |
| Feb. 1, 2026 | McManus Matthew | President - Diag & Spatial Bio | M | Restricted Stock Units | 4621 | $0.00 | 19,517.0000 | 156,999,000 | 19.14% | 0.00% |
| Feb. 1, 2026 | McManus Matthew | President - Diag & Spatial Bio | M | Common Stock | 4621 | $0.00 | 9,356.0000 | 156,999,000 | 97.59% | 0.00% |
| Feb. 1, 2026 | McManus Matthew | President - Diag & Spatial Bio | F | Common Stock | 1665 | $64.09 | 7,691.0000 | 156,999,000 | 17.80% | 0.00% |
| Nov. 3, 2025 | Hippel James | CFO | F | Common Stock | 11865 | $62.57 | 142,722.0000 | 156,362,000 | 7.68% | 0.01% |
| Nov. 3, 2025 | Hippel James | CFO | M | Restricted Stock Units | 11545 | $0.00 | 45,820.0000 | 156,362,000 | 20.13% | 0.01% |
| Nov. 3, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Common Stock | 9911 | $0.00 | 25,023.0000 | 156,362,000 | 65.58% | 0.01% |
| Nov. 3, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | F | Common Stock | 4520 | $62.57 | 20,503.0000 | 156,362,000 | 18.06% | 0.00% |
| Nov. 3, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Restricted Stock Units | 9911 | $0.00 | 14,924.0000 | 156,362,000 | 39.91% | 0.01% |
| Nov. 3, 2025 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 2303 | $62.57 | 48,665.0000 | 156,362,000 | 4.52% | 0.00% |
| Nov. 3, 2025 | Hippel James | CFO | M | Common Stock | 13159 | $0.00 | 143,042.0000 | 156,362,000 | 10.13% | 0.01% |
| Nov. 3, 2025 | Hippel James | CFO | M | Common Stock | 11545 | $0.00 | 154,587.0000 | 156,362,000 | 8.07% | 0.01% |
| Nov. 3, 2025 | Hippel James | CFO | M | Restricted Stock Units | 13159 | $0.00 | 22,731.0000 | 156,362,000 | 36.66% | 0.01% |
| Oct. 30, 2025 | Bushman Julie L | Director | A | Common Stock | 1640 | $0.00 | 8,775.0000 | 156,362,000 | 22.99% | 0.00% |
| Oct. 30, 2025 | KEEGAN JOSEPH D | Director | A | Common Stock | 1640 | $0.00 | 15,411.0000 | 156,362,000 | 11.91% | 0.00% |
| Oct. 30, 2025 | KEEGAN JOSEPH D | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 51,381.0000 | 156,362,000 | 7.93% | 0.00% |
| Oct. 30, 2025 | HIGGINS JOHN L | Director | A | Common Stock | 1640 | $0.00 | 66,876.0000 | 156,362,000 | 2.51% | 0.00% |
| Oct. 30, 2025 | HIGGINS JOHN L | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 67,321.0000 | 156,362,000 | 5.94% | 0.00% |
| Oct. 30, 2025 | Seth Alpna | Director | A | Common Stock | 1640 | $0.00 | 15,411.0000 | 156,362,000 | 11.91% | 0.00% |
| Oct. 30, 2025 | Seth Alpna | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 31,289.0000 | 156,362,000 | 13.73% | 0.00% |
| Oct. 30, 2025 | Herr Amy E. | Director | A | Common Stock | 1640 | $0.00 | 4,834.0000 | 156,362,000 | 51.35% | 0.00% |
| Oct. 30, 2025 | Herr Amy E. | Director | A | Stock Option (Right to Buy) | 3777 | $0.00 | 27,111.0000 | 156,362,000 | 16.19% | 0.00% |
| Oct. 30, 2025 | Klimovsky Judith V. | Director | A | Common Stock | 1640 | $0.00 | 3,782.0000 | 156,362,000 | 76.56% | 0.00% |
| Oct. 30, 2025 | Klimovsky Judith V. | Director | A | Stock Option (Right to Buy) | 3777 | $0.00 | 8,898.0000 | 156,362,000 | 73.76% | 0.00% |
| Oct. 30, 2025 | Vessey Rupert | Director | A | Common Stock | 1640 | $0.00 | 10,987.0000 | 156,362,000 | 17.55% | 0.00% |
| Oct. 30, 2025 | Vessey Rupert | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 33,641.0000 | 156,362,000 | 12.65% | 0.00% |
| Oct. 30, 2025 | BAUMGARTNER ROBERT V | Director | A | Common Stock | 1640 | $0.00 | 46,503.0000 | 156,362,000 | 3.66% | 0.00% |
| Oct. 30, 2025 | BAUMGARTNER ROBERT V | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 67,321.0000 | 156,362,000 | 5.94% | 0.00% |
| Oct. 30, 2025 | Bushman Julie L | Director | A | Stock Options (Right to Buy) | 3777 | $0.00 | 24,689.0000 | 156,362,000 | 18.06% | 0.00% |
| Aug. 25, 2025 | Nusse Roeland | Director | M | Common Stock | 17040 | $21.84 | 61,599.0000 | 159,717,000 | 38.24% | 0.01% |
| Aug. 25, 2025 | Nusse Roeland | Director | S | Common Stock | 17040 | $56.36 | 44,559.0000 | 159,717,000 | 27.66% | 0.01% |
| Aug. 25, 2025 | BAUMGARTNER ROBERT V | Director | M | Common Stock | 17040 | $21.84 | 61,903.0000 | 159,717,000 | 37.98% | 0.01% |
| Aug. 25, 2025 | BAUMGARTNER ROBERT V | Director | S | Common Stock | 17040 | $56.21 | 44,863.0000 | 159,717,000 | 27.53% | 0.01% |
| Aug. 25, 2025 | BAUMGARTNER ROBERT V | Director | M | Stock Options (Right to Buy) | 17040 | $0.00 | 63,544.0000 | 159,717,000 | 21.15% | 0.01% |
| Aug. 25, 2025 | Nusse Roeland | Director | M | Stock Options (Right to Buy) | 17040 | $0.00 | 63,544.0000 | 159,717,000 | 21.15% | 0.01% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Performance Restricted Stock Units | 19355 | $0.00 | 44,167.0000 | 159,717,000 | 78.01% | 0.01% |
| Aug. 15, 2025 | Hippel James | CFO | A | Performance Restricted Stock Units | 29420 | $0.00 | 67,347.0000 | 159,717,000 | 77.57% | 0.02% |
| Aug. 15, 2025 | Hippel James | CFO | A | Restricted Stock Units | 14710 | $0.00 | 62,503.0000 | 159,717,000 | 30.78% | 0.01% |
| Aug. 15, 2025 | Hippel James | CFO | A | Stock Options (Right to Buy) | 37632 | $0.00 | 555,124.0000 | 159,717,000 | 7.27% | 0.02% |
| Aug. 15, 2025 | Herr Amy E. | Director | M | Common Stock | 279 | $0.00 | 3,295.0000 | 159,717,000 | 9.25% | 0.00% |
| Aug. 15, 2025 | Herr Amy E. | Director | F | Common Stock | 101 | $53.60 | 3,194.0000 | 159,717,000 | 3.07% | 0.00% |
| Aug. 15, 2025 | Herr Amy E. | Director | M | Restricted Stock Units | 119 | $0.00 | 233.0000 | 159,717,000 | 33.81% | 0.00% |
| Aug. 15, 2025 | Herr Amy E. | Director | M | Restricted Stock Units | 160 | $0.00 | 435.0000 | 159,717,000 | 26.89% | 0.00% |
| Aug. 15, 2025 | Herr Amy E. | Director | A | Restricted Stock Units | 932 | $0.00 | 1,047.0000 | 159,717,000 | 810.43% | 0.00% |
| Aug. 15, 2025 | Herr Amy E. | Director | A | Stock Option (Right to Buy) | 2735 | $0.00 | 23,334.0000 | 159,717,000 | 13.28% | 0.00% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 8543 | $0.00 | 55,273.0000 | 159,717,000 | 18.28% | 0.01% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 4305 | $53.60 | 50,968.0000 | 159,717,000 | 7.79% | 0.00% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | M | Restricted Stock Units | 8543 | $0.00 | 17,087.0000 | 159,717,000 | 33.33% | 0.01% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | A | Performance Restricted Stock Units | 70708 | $0.00 | 140,265.0000 | 159,717,000 | 101.65% | 0.04% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | A | Restricted Stock Units | 35354 | $0.00 | 35,354.0000 | 159,717,000 | 9999.99% | 0.02% |
| Aug. 15, 2025 | Kelderman Kim | Chief Executive Officer | A | Stock Options (Right to Buy) | 90441 | $0.00 | 307,975.0000 | 159,717,000 | 41.58% | 0.06% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | M | Common Stock | 1718 | $0.00 | 4,912.0000 | 159,717,000 | 53.79% | 0.00% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | F | Common Stock | 527 | $53.60 | 4,385.0000 | 159,717,000 | 10.73% | 0.00% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | M | Restricted Stock Units | 50 | $0.00 | 2,308.0000 | 159,717,000 | 2.12% | 0.00% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | M | Restricted Stock Units | 1668 | $0.00 | 5,597.0000 | 159,717,000 | 22.96% | 0.00% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | A | Performance Restricted Stock Units | 13992 | $0.00 | 28,806.0000 | 159,717,000 | 94.45% | 0.01% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | A | Restricted Stock Units | 6996 | $0.00 | 9,255.0000 | 159,717,000 | 309.69% | 0.00% |
| Aug. 15, 2025 | Bohnen Shane | SVP - General Counsel | A | Stock Option (Right to Buy) | 17897 | $0.00 | 76,375.0000 | 159,717,000 | 30.60% | 0.01% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | M | Common Stock | 2637 | $0.00 | 5,615.0000 | 159,717,000 | 88.55% | 0.00% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | F | Common Stock | 880 | $53.60 | 4,735.0000 | 159,717,000 | 15.67% | 0.00% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | M | Restricted Stock Units | 2637 | $0.00 | 14,516.0000 | 159,717,000 | 15.37% | 0.00% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | A | Performance Restricted Stock Units | 19243 | $0.00 | 37,956.0000 | 159,717,000 | 102.83% | 0.01% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | A | Restricted Stock Units | 9622 | $0.00 | 18,863.0000 | 159,717,000 | 104.12% | 0.01% |
| Aug. 15, 2025 | McManus Matthew | President - Diag & Spatial Bio | A | Stock Option (Right to Buy) | 24614 | $0.00 | 61,836.0000 | 159,717,000 | 66.13% | 0.02% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Common Stock | 2623 | $0.00 | 15,915.0000 | 159,717,000 | 19.73% | 0.00% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | F | Common Stock | 803 | $53.60 | 15,112.0000 | 159,717,000 | 5.05% | 0.00% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Restricted Stock Units | 2623 | $0.00 | 15,157.0000 | 159,717,000 | 14.75% | 0.00% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Restricted Stock Units | 9678 | $0.00 | 19,589.0000 | 159,717,000 | 97.65% | 0.01% |
| Aug. 15, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Stock Options (Right to Buy) | 24758 | $0.00 | 121,533.0000 | 159,717,000 | 25.58% | 0.02% |
| Aug. 15, 2025 | Hippel James | CFO | M | Common Stock | 4010 | $0.00 | 131,809.0000 | 159,717,000 | 3.14% | 0.00% |
| Aug. 15, 2025 | Hippel James | CFO | F | Common Stock | 1926 | $53.60 | 129,883.0000 | 159,717,000 | 1.46% | 0.00% |
| Aug. 15, 2025 | Hippel James | CFO | M | Restricted Stock Units | 4010 | $0.00 | 55,814.0000 | 159,717,000 | 6.70% | 0.00% |
| Aug. 7, 2025 | HIGGINS JOHN L | Director | M | Stock Option (Right to Buy) | 5040 | $0.00 | 63,544.0000 | 159,717,000 | 7.35% | 0.00% |
| Aug. 7, 2025 | HIGGINS JOHN L | Director | M | Common Stock | 5040 | $21.84 | 65,236.0000 | 159,717,000 | 8.37% | 0.00% |
| July 29, 2025 | Hippel James | CFO | M | Stock Options (Right to Buy) | 168620 | $0.00 | 517,492.0000 | 159,717,000 | 24.58% | 0.11% |
| July 29, 2025 | Hippel James | CFO | M | Common Stock | 168620 | $44.33 | 275,230.0000 | 159,717,000 | 158.17% | 0.11% |
| July 29, 2025 | Hippel James | CFO | F | Common Stock | 147431 | $58.55 | 127,799.0000 | 159,717,000 | 53.57% | 0.09% |
| July 22, 2025 | Kelderman Kim | Chief Executive Officer | M | Stock Option (Right to Buy) | 48176 | $0.00 | 251,204.0000 | 159,717,000 | 16.09% | 0.03% |
| July 22, 2025 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 43649 | $53.12 | 46,730.0000 | 159,717,000 | 48.30% | 0.03% |
| July 22, 2025 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 48176 | $44.33 | 90,379.0000 | 159,717,000 | 114.15% | 0.03% |
| July 15, 2025 | Kelderman Kim | Chief Executive Officer | M | Stock Option (Right to Buy) | 36132 | $0.00 | 299,380.0000 | 159,717,000 | 10.77% | 0.02% |
| July 15, 2025 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 36132 | $44.33 | 75,136.0000 | 159,717,000 | 92.64% | 0.02% |
| July 15, 2025 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 32933 | $51.42 | 42,203.0000 | 159,717,000 | 43.83% | 0.02% |
| June 9, 2025 | Herr Amy E. | Director | M | Stock Option (Right to Buy) | 1280 | $0.00 | 20,599.0000 | 158,944,000 | 5.85% | 0.00% |
| June 9, 2025 | Herr Amy E. | Director | M | Common Stock | 1280 | $44.33 | 4,296.0000 | 158,944,000 | 42.44% | 0.00% |
| June 9, 2025 | Herr Amy E. | Director | S | Common Stock | 1280 | $49.77 | 3,016.0000 | 158,944,000 | 29.80% | 0.00% |
| May 1, 2025 | HIGGINS JOHN L | Director | M | Common Stock | 12000 | $21.84 | 60,196.0000 | 158,944,000 | 24.90% | 0.01% |
| May 1, 2025 | HIGGINS JOHN L | Director | M | Stock Options (Right to Buy) | 12000 | $0.00 | 68,584.0000 | 158,944,000 | 14.89% | 0.01% |
| July 1, 2019 | VESSEY RUPERT | Director | A | Stock Options (Right to Buy) | 588 | $0.00 | 588.0000 | 39,135,000 | 9999.99% | 0.00% |
| April 3, 2025 | Bohnen Shane | SVP - General Counsel | M | Restricted Stock Units | 2260 | $0.00 | 7,364.0000 | 158,944,000 | 23.48% | 0.00% |
| April 3, 2025 | Bohnen Shane | SVP - General Counsel | F | Common Stock | 747 | $54.86 | 3,194.0000 | 158,944,000 | 18.95% | 0.00% |
| April 3, 2025 | Bohnen Shane | SVP - General Counsel | M | Common Stock | 2260 | $0.00 | 3,941.0000 | 158,944,000 | 134.44% | 0.00% |
| Feb. 14, 2025 | Herr Amy E. | Director | M | Common Stock | 1976 | $44.33 | 4,876.0000 | 160,626,000 | 68.14% | 0.00% |
| Feb. 14, 2025 | Herr Amy E. | Director | S | Common Stock | 1860 | $65.96 | 3,016.0000 | 160,626,000 | 38.15% | 0.00% |
| Feb. 14, 2025 | Herr Amy E. | Director | M | Stock Option (Right to Buy) | 1976 | $0.00 | 21,879.0000 | 160,626,000 | 8.28% | 0.00% |
| Feb. 3, 2025 | Herr Amy E. | Director | A | Stock Option (Right to Buy) | 344 | $0.00 | 23,855.0000 | 160,626,000 | 1.46% | 0.00% |
| Feb. 3, 2025 | Herr Amy E. | Director | A | Common Stock | 1040 | $0.00 | 2,900.0000 | 160,626,000 | 55.91% | 0.00% |
| Feb. 3, 2025 | Herr Amy E. | Director | A | Stock Option (Right to Buy) | 2415 | $0.00 | 23,855.0000 | 160,626,000 | 11.26% | 0.00% |
| Feb. 3, 2025 | Herr Amy E. | Director | A | Restricted Stock Units | 115 | $0.00 | 832.0000 | 160,626,000 | 16.04% | 0.00% |
| Feb. 1, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | F | Common Stock | 1109 | $73.55 | 13,292.0000 | 160,626,000 | 7.70% | 0.00% |
| Feb. 1, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Restricted Stock Units | 3320 | $0.00 | 17,780.0000 | 160,626,000 | 15.73% | 0.00% |
| Feb. 1, 2025 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Common Stock | 3320 | $0.00 | 14,401.0000 | 160,626,000 | 29.96% | 0.00% |
| Feb. 1, 2025 | McManus Matthew | President - DGS | M | Restricted Stock Units | 4620 | $0.00 | 17,153.0000 | 160,626,000 | 21.22% | 0.00% |
| Feb. 1, 2025 | McManus Matthew | President - DGS | F | Common Stock | 1642 | $73.55 | 2,978.0000 | 160,626,000 | 35.54% | 0.00% |
| Feb. 1, 2025 | McManus Matthew | President - DGS | M | Common Stock | 4620 | $0.00 | 4,620.0000 | 160,626,000 | 9999.99% | 0.00% |
| Aug. 15, 2024 | McManus Matthew | President - DGS | A | Performance Restricted Stock Units | 15825 | $0.00 | 15,825.0000 | 160,774,000 | 9999.99% | 0.01% |
| Jan. 27, 2025 | Kelderman Kim | Chief Executive Officer | S | Common Stock | 1661 | $77.95 | 39,004.0000 | 160,626,000 | 4.08% | 0.00% |
| Jan. 27, 2025 | Kelderman Kim | Chief Executive Officer | M | Stock Option (Right to Buy) | 13392 | $0.00 | 335,512.0000 | 160,626,000 | 3.84% | 0.01% |
| Jan. 27, 2025 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 13392 | $37.70 | 52,396.0000 | 160,626,000 | 34.33% | 0.01% |
| Jan. 27, 2025 | Kelderman Kim | Chief Executive Officer | S | Common Stock | 11731 | $77.19 | 40,665.0000 | 160,626,000 | 22.39% | 0.01% |
| Nov. 1, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Restricted Stock Units | 9912 | $0.00 | 21,100.0000 | 161,115,000 | 31.96% | 0.01% |
| Nov. 1, 2024 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 2430 | $75.31 | 39,004.0000 | 161,115,000 | 5.86% | 0.00% |
| Nov. 1, 2024 | Hippel James | CFO | M | Common Stock | 13159 | $0.00 | 113,085.0000 | 161,115,000 | 13.17% | 0.01% |
| Nov. 1, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | M | Common Stock | 9912 | $0.00 | 14,351.0000 | 161,115,000 | 223.29% | 0.01% |
| Nov. 1, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | F | Common Stock | 3270 | $75.31 | 11,081.0000 | 161,115,000 | 22.79% | 0.00% |
| Nov. 1, 2024 | Hippel James | CFO | A | Restricted Stock Units | 34634 | $0.00 | 46,665.0000 | 161,115,000 | 287.87% | 0.02% |
| Nov. 1, 2024 | Hippel James | CFO | F | Common Stock | 6475 | $75.31 | 106,610.0000 | 161,115,000 | 5.73% | 0.00% |
| Nov. 1, 2024 | Hippel James | CFO | M | Restricted Stock Units | 13159 | $0.00 | 25,190.0000 | 161,115,000 | 34.31% | 0.01% |
| Oct. 24, 2024 | Seth Alpna | Director | A | Common Stock | 1462 | $0.00 | 13,771.0000 | 161,115,000 | 11.88% | 0.00% |
| Oct. 24, 2024 | Nusse Roeland | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 80,584.0000 | 161,115,000 | 4.56% | 0.00% |
| Oct. 24, 2024 | Nusse Roeland | Director | A | Common Stock | 1462 | $0.00 | 44,559.0000 | 161,115,000 | 3.39% | 0.00% |
| Oct. 24, 2024 | HIGGINS JOHN L | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 80,584.0000 | 161,115,000 | 4.56% | 0.00% |
| Oct. 24, 2024 | HIGGINS JOHN L | Director | A | Common Stock | 1462 | $0.00 | 48,196.0000 | 161,115,000 | 3.13% | 0.00% |
| Oct. 24, 2024 | Bushman Julie L | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 20,912.0000 | 161,115,000 | 20.18% | 0.00% |
| Oct. 24, 2024 | Bushman Julie L | Director | A | Common Stock | 1462 | $0.00 | 7,135.0000 | 161,115,000 | 25.77% | 0.00% |
| Oct. 24, 2024 | VESSEY RUPERT | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 29,864.0000 | 161,115,000 | 13.32% | 0.00% |
| Oct. 24, 2024 | VESSEY RUPERT | Director | A | Common Stock | 1462 | $0.00 | 9,347.0000 | 161,115,000 | 18.54% | 0.00% |
| Oct. 24, 2024 | KEEGAN JOSEPH D | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 47,604.0000 | 161,115,000 | 7.96% | 0.00% |
| Oct. 24, 2024 | KEEGAN JOSEPH D | Director | A | Common Stock | 1462 | $0.00 | 13,771.0000 | 161,115,000 | 11.88% | 0.00% |
| Oct. 24, 2024 | BAUMGARTNER ROBERT V | Director | A | Common Stock | 1462 | $0.00 | 44,863.0000 | 161,115,000 | 3.37% | 0.00% |
| Oct. 24, 2024 | BAUMGARTNER ROBERT V | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 80,584.0000 | 161,115,000 | 4.56% | 0.00% |
| Oct. 24, 2024 | Klimovsky Judith V | Director | A | Stock Option (Right to Buy) | 3511 | $0.00 | 5,121.0000 | 161,115,000 | 218.07% | 0.00% |
| Oct. 24, 2024 | Klimovsky Judith V | Director | A | Common Stock | 1462 | $0.00 | 2,142.0000 | 161,115,000 | 215.00% | 0.00% |
| Oct. 24, 2024 | Seth Alpna | Director | A | Stock Options (Right to Buy) | 3511 | $0.00 | 27,512.0000 | 161,115,000 | 14.63% | 0.00% |
| Sept. 12, 2024 | HIGGINS JOHN L | Director | M | Common Stock | 6000 | $22.95 | 48,608.0000 | 160,774,000 | 14.08% | 0.00% |
| Sept. 12, 2024 | HIGGINS JOHN L | Director | F | Common Stock | 1874 | $73.20 | 46,734.0000 | 160,774,000 | 3.86% | 0.00% |
| Sept. 12, 2024 | HIGGINS JOHN L | Director | M | Stock Options (Right to Buy) | 6000 | $0.00 | 77,073.0000 | 160,774,000 | 7.22% | 0.00% |
| Aug. 29, 2024 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 1492 | $66.97 | 41,434.0000 | 160,774,000 | 3.74% | 0.00% |
| Aug. 29, 2024 | Kelderman Kim | Chief Executive Officer | M | Stock Option (Right to Buy) | 1492 | $0.00 | 348,904.0000 | 160,774,000 | 0.43% | 0.00% |
| Aug. 15, 2024 | McManus Matthew | President - DGS | A | Restricted Stock Units | 7912 | $0.00 | 21,773.0000 | 160,774,000 | 57.08% | 0.00% |
| Aug. 15, 2024 | McManus Matthew | President - DGS | A | Performance Restricted Stock Units | 15818 | $0.00 | 18,706.0000 | 160,774,000 | 547.71% | 0.01% |
| Aug. 15, 2024 | Hippel James | CFO | A | Performance Restricted Stock Units | 24062 | $0.00 | 48,839.0000 | 160,774,000 | 97.11% | 0.01% |
| Aug. 15, 2024 | Hippel James | CFO | A | Restricted Stock Units | 12031 | $0.00 | 38,349.0000 | 160,774,000 | 45.71% | 0.01% |
| Aug. 15, 2024 | Hippel James | CFO | A | Stock Options (Right to Buy) | 32417 | $0.00 | 739,979.0000 | 160,774,000 | 4.58% | 0.02% |
| Aug. 15, 2024 | Kelderman Kim | Chief Executive Officer | A | Performance Restricted Stock Units | 51261 | $0.00 | 76,541.0000 | 160,774,000 | 202.77% | 0.03% |
| Aug. 15, 2024 | Kelderman Kim | Chief Executive Officer | A | Restricted Stock Units | 25630 | $0.00 | 25,630.0000 | 160,774,000 | 9999.99% | 0.02% |
| Aug. 15, 2024 | Kelderman Kim | Chief Executive Officer | A | Stock Options (Right to Buy) | 69061 | $0.00 | 217,534.0000 | 160,774,000 | 46.51% | 0.04% |
| Aug. 15, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Performance Restricted Stock Units | 15738 | $0.00 | 31,952.0000 | 160,774,000 | 97.06% | 0.01% |
| Aug. 15, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Restricted Stock Units | 7869 | $0.00 | 31,012.0000 | 160,774,000 | 34.00% | 0.00% |
| Aug. 15, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | A | Stock Options (Right to Buy) | 21204 | $0.00 | 96,775.0000 | 160,774,000 | 28.06% | 0.01% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | M | Common Stock | 49 | $0.00 | 1,696.0000 | 160,774,000 | 2.98% | 0.00% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | F | Common Stock | 15 | $74.91 | 1,681.0000 | 160,774,000 | 0.88% | 0.00% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | M | Restricted Stock Units | 49 | $0.00 | 4,618.0000 | 160,774,000 | 1.05% | 0.00% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | A | Performance Restricted Stock Units | 10012 | $0.00 | 14,814.0000 | 160,774,000 | 208.50% | 0.01% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | A | Stock Option (Right to Buy) | 13488 | $0.00 | 58,478.0000 | 160,774,000 | 29.98% | 0.01% |
| Aug. 15, 2024 | Bohnen Shane | SVP - General Counsel | A | Restricted Stock Units | 5006 | $0.00 | 9,525.0000 | 160,774,000 | 110.78% | 0.00% |
| Aug. 15, 2024 | McManus Matthew | President - DGS | A | Stock Option (Right to Buy) | 21320 | $0.00 | 37,222.0000 | 160,774,000 | 134.07% | 0.01% |
| Aug. 8, 2024 | BAUMGARTNER ROBERT V | Director | S | Common Stock | 16000 | $72.10 | 43,401.0000 | 160,774,000 | 26.94% | 0.01% |
| Aug. 8, 2024 | BAUMGARTNER ROBERT V | Director | M | Common Stock | 16000 | $22.95 | 59,401.0000 | 160,774,000 | 36.87% | 0.01% |
| Aug. 8, 2024 | BAUMGARTNER ROBERT V | Director | M | Stock Options (Right to Buy) | 16000 | $0.00 | 77,073.0000 | 160,774,000 | 17.19% | 0.01% |
| Aug. 2, 2024 | Hippel James | CFO | M | Stock Options (Right to Buy) | 53000 | $0.00 | 707,562.0000 | 160,774,000 | 6.97% | 0.03% |
| Aug. 2, 2024 | Hippel James | CFO | F | Common Stock | 36076 | $82.35 | 99,926.0000 | 160,774,000 | 26.53% | 0.02% |
| Aug. 2, 2024 | Hippel James | CFO | M | Common Stock | 53000 | $31.26 | 136,002.0000 | 160,774,000 | 63.85% | 0.03% |
| July 31, 2024 | Kelderman Kim | Chief Executive Officer | M | Common Stock | 14000 | $37.70 | 49,421.0000 | 160,774,000 | 39.52% | 0.01% |
| July 31, 2024 | Kelderman Kim | Chief Executive Officer | F | Common Stock | 9479 | $81.97 | 39,942.0000 | 160,774,000 | 19.18% | 0.01% |
| July 31, 2024 | Kelderman Kim | Chief Executive Officer | M | Stock Option (Right to Buy) | 14000 | $0.00 | 350,396.0000 | 160,774,000 | 3.84% | 0.01% |
| July 23, 2024 | Hippel James | CFO | M | Common Stock | 35000 | $31.26 | 107,284.0000 | 160,774,000 | 48.42% | 0.02% |
| July 23, 2024 | Hippel James | CFO | F | Common Stock | 24282 | $77.77 | 83,002.0000 | 160,774,000 | 22.63% | 0.02% |
| July 23, 2024 | Hippel James | CFO | M | Stock Options (Right to Buy) | 35000 | $0.00 | 760,562.0000 | 160,774,000 | 4.40% | 0.02% |
| July 8, 2024 | HIGGINS JOHN L | Director | M | Common Stock | 6000 | $22.95 | 42,608.0000 | 160,774,000 | 16.39% | 0.00% |
| July 8, 2024 | HIGGINS JOHN L | Director | M | Stock Options (Right to Buy) | 6000 | $0.00 | 83,073.0000 | 160,774,000 | 6.74% | 0.00% |
| May 14, 2024 | HIGGINS JOHN L | Director | S | Common Stock | 4000 | $83.84 | 36,608.0000 | 160,496,000 | 9.85% | 0.00% |
| May 14, 2024 | HIGGINS JOHN L | Director | M | Common Stock | 4000 | $22.95 | 40,608.0000 | 160,496,000 | 10.93% | 0.00% |
| May 14, 2024 | HIGGINS JOHN L | Director | M | Stock Options (Right to Buy) | 4000 | $0.00 | 89,073.0000 | 160,496,000 | 4.30% | 0.00% |
| May 1, 2024 | Klimovsky Judith V | Director | A | Common Stock | 680 | $0.00 | 680.0000 | 160,496,000 | 9999.99% | 0.00% |
| May 1, 2024 | Klimovsky Judith V | Director | A | Stock Option (Right to Buy) | 1610 | $0.00 | 1,610.0000 | 160,496,000 | 9999.99% | 0.00% |
| April 3, 2024 | Bohnen Shane | SVP - General Counsel | M | Restricted Stock Units | 2259 | $0.00 | 4,519.0000 | 160,496,000 | 33.33% | 0.00% |
| April 3, 2024 | Bohnen Shane | SVP - General Counsel | M | Common Stock | 2259 | $0.00 | 2,394.0000 | 160,496,000 | 1673.33% | 0.00% |
| April 3, 2024 | Bohnen Shane | SVP - General Counsel | F | Common Stock | 747 | $67.87 | 1,647.0000 | 160,496,000 | 31.20% | 0.00% |
| March 7, 2024 | Nusse Roeland | Director | S | Common Stock | 10400 | $76.98 | 43,097.0000 | 160,060,000 | 19.44% | 0.01% |
| Feb. 1, 2024 | McManus Matthew | President - DGS | A | Stock Option (Right to Buy) | 7951 | $0.00 | 7,951.0000 | 160,060,000 | 9999.99% | 0.00% |
| Feb. 1, 2024 | McManus Matthew | President - DGS | A | Stock Option (Right to Buy) | 15902 | $0.00 | 15,902.0000 | 160,060,000 | 9999.99% | 0.01% |
| Feb. 1, 2024 | Geist William | PRESIDENT, PROTEIN SCIENCES | F | Common Stock | 1111 | $68.54 | 7,759.0000 | 160,060,000 | 12.53% | 0.00% |
| Feb. 1, 2024 | McManus Matthew | President - DGS | A | Restricted Stock Units | 2888 | $0.00 | 2,888.0000 | 160,060,000 | 9999.99% | 0.00% |
| Feb. 1, 2024 | McManus Matthew | President - DGS | A | Restricted Stock Units | 13861 | $0.00 | 13,861.0000 | 160,060,000 | 9999.99% | 0.01% |
| Feb. 1, 2024 | Kelderman Kim | Chief Operating Officer | A | Stock Options (Right to Buy) | 51890 | $0.00 | 194,058.0000 | 160,060,000 | 36.50% | 0.03% |
| Feb. 1, 2024 | Kelderman Kim | Chief Operating Officer | A | Stock Options (Right to Buy) | 25945 | $0.00 | 168,113.0000 | 160,060,000 | 18.25% | 0.02% |
| Feb. 1, 2024 | Kelderman Kim | Chief Operating Officer | A | Restricted Stock Units | 9423 | $0.00 | 30,260.0000 | 160,060,000 | 45.22% | 0.01% |